Campaign

CRO#: 759257

ArrayPatch

MedTech

ArrayPatch has developed an award-winning dissolving microneedle patch technology to deliver drug therapies for a number of conditions in a safer more effective way.
by Dr. Waleed Faisal
Cork
87% Funded
€ 1,800,000 Funding goal
€ 1,563,900 Invested
9Investors


Company Summary :

 

ArrayPatch is developing a patented dissolving microneedle drug delivery platform called DerMap, effective delivery of medicines through the skin. Its lead product, ITZ-DerMap, targets nail fungal infections, with further applications in skin cancer, weight loss, diabetes and migraine.

 

Key highlights: 

  • Winner of the InterTradeIreland All-Island Seedcorn Investor Readiness Competition 2025.
  • DerMap-Breakthrough platform technology attracting strong industry interest.
  • Protected by patent filings in multiple jurisdictions.
  • The lead product from platform, ITZ-Dermap™, targets nail fungal infections-a disease that affects 1 in 4 people globally.
  • Global nail fungal treatment market valued at $4.7bn in 2022, projected to reach $6.2bn by 2027.
  • Proof of concept completed with strong preclinical data indicating commercial potential.
  • ITZ-DerMap™ has potential to deliver superior patient outcomes-higher cure rates and shorter treatment times versus current treatments, and higher compliance.
  • Additional DerMap applications include skin cancer, migraine, diabetes and weight loss-markets worth >$70bn.
  • Enterprise Ireland HPSU company.
  • More than €1.3m invested in the technology prior to spin-out from UCC.
  • Raising seed round with €1.68m in equity investment committed.
  • Lead investor: Lakeside Capital.
  • Platform technology provides multiple exit avenues for investors.
  • World class management team accumulating more than 75 years of commercial and industrial experience.

 

  • Campaign Story
  • Team
  • Documents
  • FAQ
  • Updates
  • Discussion

Risk warning

Investment in this crowdfunding project entails risk, including the risk of partial or entire loss of the money invested. Your investment is not covered by the deposit guarantee schemes established in accordance with Directive 2014/49/EU of the European Parliament and of the Council. Nor is your investment covered by the investor compensation schemes established in accordance with the Directive 97/9/EC of the European Parliament and of the Council.

Investments that qualify for tax relief schemes (such as EIIS) may lose that status due to the company’s future activities or your personal circumstances. Any tax relief is not guaranteed and should not be the primary reason for investment. You should consult your tax advisor.

You may not receive any return on your investment.

This is not a savings product and we advise you not to invest any more than 10% of your net worth in crowdfunding projects.

You may not be able to sell the investment instruments when you wish. If you are able to sell them, you may nonetheless incur losses.

The crowdfunding service provider declares that, to the best of its knowledge, no information has been omitted or is materially misleading or inaccurate. The crowdfunding service provider is responsible for the preparation of this key investment information sheet. You may not receive any return on your investment.

Please click here to read our full Risk Warning.

Spark Venture Funding is authorised by the Central Bank of Ireland.